MONDAY, Oct. 29 (HealthDay News) -- Massachusetts officials have closed a second compounding pharmacy after a snap inspection last week revealed conditions that might threaten the sterility of its products.
According to The New York Times, Waltham, Mass.-based Infusion Resource voluntarily surrendered its license over the weekend after inspectors found "significant issues with the environment in which medications were being compounded," Dr. Madeleine Biondolillo, director of the Bureau of Health Care Safety and Quality at the Massachusetts Public Health Department, said at a press briefing.
While she did not release details of what the inspection found, Biondolillo did say that patients had been receiving intravenous medications at the pharmacy, violating state law.
The pharmacy shutdown came after revelations of unsanitary conditions at the Framingham, Mass., facility of New England Compounding Center, the plant at the center of the ongoing meningitis outbreak. On Friday, federal investigators said their tour of the plant found foreign, "greenish-black" material in some vials of the injectable steroid suspected as the cause of the illnesses.
The contaminated product was one of a host of potential violations discovered during a recent inspection of the New England Compounding Center's plant in Framingham, Mass., U.S. Food and Drug Administration officials said during a Friday press briefing.
"The investigators observed approximately 100 vials of the steroid drug, which purports to be a sterile injectable drug, that had a greenish-black foreign material and a white filamentous [containing filaments] material inside," Steven Lynn, director of the U.S. Food and Drug Administration's Office of Manufacturing and Product Quality, said during a news conference Friday afternoon.
As of Saturday, the U.S. Centers for Disease Control
All rights reserved